Quotient Limited Announces Manuel Mendez as Chief Executive Officer
February 23 2021 - 6:20AM
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics
company (the Company), today announced that Manuel Mendez has been
appointed as Chief Executive Officer of the Company and will begin
serving in that role on April 1st, 2021. Franz Walt, who has served
as the company’s CEO since 2018 is retiring.
“We are very confident, that Manuel is the right
leader,” said Heino von Prondzynski, Chairman of Quotient’s Board
of Directors. “His background and experience make him ideally
suited to guide the Company through its very important next phase,
commercialization of our revolutionary MosaiQ platform, first in
transfusion diagnostics and then in other, potentially even more
promising applications.”
Manuel joins Quotient from Quest Diagnostics
(NYSE: DGX), the world’s leading provider of diagnostic information
services where he served as the Senior Vice President and Chief
Commercial Officer. He played a key role in accelerating
growth and supporting the COVID-19 efforts.
Manuel brings over 30 years of experience in the
diagnostic and life science markets. Before joining Quest, he was
living in Germany and served as SVP and Head of Global Commercial
Operations and a member of QIAGEN N.V. Executive Committee, a
worldwide provider of Sample to Insight solutions
for molecular testing. Manuel has held a variety of
senior leadership roles with Abbott Laboratories, Thermo Fisher
Scientific, OraSure Technologies, and bioMerieux – living
in the United States, Europe, Asia, and Latin
America.
Manuel received an MBA from Northwestern
University's Kellogg School of Management and a bachelor's
degree in biomedical engineering from Boston
University.
“I’m excited to join the talented Quotient team
to bring the innovative MosaiQ solution to the transfusion
diagnostics market,” said Mr. Mendez.
Company Board Chairman Mr. von Prondzynski
expressed the Board's gratitude and appreciation to Mr. Walt for
his service. Mr. Walt came out of retirement to serve as the
Company's CEO beginning in 2018. “Franz, who is a very good friend,
always said that he planned to serve only until we found the right
candidate to take over as CEO,” said Mr. von Prondzynski. “Franz
did an outstanding job. He and his team accomplished their goal of
preparing the MosaiQ system for commercialization, by obtaining the
first five MosaiQ CE marks and one U.S. FDA Emergency Use
Authorization (EUA) for the Company's Covid Antibody test.”
“I would like to take the opportunity to thank
the Board for their support and trust. I feel honored to be part of
the Quotient and MosaiQ legacy, it was an exciting time and I wish
the entire team success as they continue to grow the business,”
said Franz Walt.
About Quotient Limited
Building on over 30 years of experience in
transfusion diagnostics, Quotient is a commercial-stage diagnostics
company committed to delivering solutions that reshape the way
diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex
microarray technology, offers the world’s first fully automated,
consolidated testing platform, allowing for multiple tests across
different modalities. MosaiQ is designed to be a game-changing
solution, which Quotient believes will increase efficiencies,
improve clinical practice, deliver significant workflow
improvements, and operational cost savings to laboratories around
the world. In response to the global effort to combat COVID-19,
Quotient developed the MosaiQ COVID-19 Antibody Microarray which is
CE marked and has received the U.S. FDA Emergency Use
Authorization. Quotient's operations are based in Eysins,
Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo, Quotient MosaiQ and MosaiQ
are trademarks or registered trademarks of Quotient Limited or its
subsidiaries in various jurisdictions.
Contact: Peter Buhler, Chief
Financial Officer, IR@quotientbd.com; +41 22 545 52 26
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Apr 2023 to Apr 2024